Limits...
Serum Golgi protein 73 (GP73) is a diagnostic and prognostic marker of chronic HBV liver disease.

Xu Z, Liu L, Pan X, Wei K, Wei M, Liu L, Yang H, Liu Q - Medicine (Baltimore) (2015)

Bottom Line: In patients with normal ALT levels, serum GP73 concentrations were significantly higher in patients with prominent hepatic inflammatory injury and fibrosis than in patients without hepatic inflammatory injury or fibrosis.Serum GP73 concentrations and GP73 protein expression were decreased in the liver tissues of patients whose ALT levels normalized after 1 year of ETV antiviral therapy.Changes in serum GP73 levels were closely associated with changes in liver injury severity, and, therefore, GP73 may be an effective new liver inflammatory injury biomarker, and could be useful for monitoring the prognosis of chronic HBV infectious patients with normal ALT levels.

View Article: PubMed Central - PubMed

Affiliation: From the Clinical Liver Center (ZX, Liguan Liu, XP, HY, QL); Central Laboratory of Clinical Hepatology (KW, MW); and Department of Pathology (Lifei Liu), The 180th Hospital of the People's Liberation Army, Quanzhou, China.

ABSTRACT
Alanine aminotransferase (ALT) is the most commonly used marker of liver injury, but normal ALT levels are seen in a proportion of chronic hepatitis B virus (HBV)-infected patients with severe liver injury. Golgi protein 73 (GP73) is a promising alternative marker of liver injury. This study assessed the relation between GP73 levels and liver disease severity, monitored the kinetic changes in GP73 levels in chronic HBV patients receiving entecavir (ETV) therapy, and investigated the potential diagnostic and prognostic values of serum GP73 as a new liver injury biomarker in chronic HBV infections. This study enrolled 1150 patients with chronic HBV infections, 200 of whom were retrospectively enrolled in this study after receiving 1 year of ETV treatment. GP73 expression in liver tissue was detected by immunohistochemistry. GP73 levels in single or serial serum samples were measured by enzyme-linked immunosorbent assay. Immunohistochemical analysis indicated that GP73 protein expression in the liver increased progressively with pathologic progression from nonexistent or mild hepatitis to severe hepatitis and cirrhosis during chronic HBV infection. Serum GP73 levels were positively correlated with the disease severity of chronic HBV infections (r = 0.58, P < 0.001). In patients with normal ALT levels, serum GP73 concentrations were significantly higher in patients with prominent hepatic inflammatory injury and fibrosis than in patients without hepatic inflammatory injury or fibrosis. Serum GP73 concentrations and GP73 protein expression were decreased in the liver tissues of patients whose ALT levels normalized after 1 year of ETV antiviral therapy. Changes in serum GP73 levels were closely associated with changes in liver injury severity, and, therefore, GP73 may be an effective new liver inflammatory injury biomarker, and could be useful for monitoring the prognosis of chronic HBV infectious patients with normal ALT levels.

Show MeSH

Related in: MedlinePlus

GP73 protein expression in normal and chronic HBV-infected liver tissues. (A) IHC showed that a majority of hepatocytes in the normal liver tissue were negative for GP73 protein expression. (B) Weak GP73 staining was detected in the liver of a HBV-C patient without prominent necroinflammation. (C) Many hepatocytes were detected with moderate GP73 staining in the moderately inflamed liver. Strong GP73 positivity was detected in the liver with severe chronic hepatitis B (D), compensated liver cirrhosis (E), and HCC (F). (Magnification, ×200). HBV-C = HBV carriers, HCC = HBV-related primary hepatocellular carcinoma, IHC = immunohistochemical.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4554005&req=5

Figure 1: GP73 protein expression in normal and chronic HBV-infected liver tissues. (A) IHC showed that a majority of hepatocytes in the normal liver tissue were negative for GP73 protein expression. (B) Weak GP73 staining was detected in the liver of a HBV-C patient without prominent necroinflammation. (C) Many hepatocytes were detected with moderate GP73 staining in the moderately inflamed liver. Strong GP73 positivity was detected in the liver with severe chronic hepatitis B (D), compensated liver cirrhosis (E), and HCC (F). (Magnification, ×200). HBV-C = HBV carriers, HCC = HBV-related primary hepatocellular carcinoma, IHC = immunohistochemical.

Mentions: GP73 expression was detected in liver tissues of 16 patients with chronic hepatitis B. IHC staining results showed that a majority of hepatocytes in the normal liver tissue were negative for GP73 protein expression (Figure 1A). In patients with chronic HBV infections, GP73 was expressed with a scattered pattern in the cytoplasm of hepatocytes, but not in the infiltrating inflammatory cells. The detected GP73 positive cell percentages in HBV-C, CHB, severe hepatitis, compensated LC and HCC patients were about 15.00%, 45.00%, 75.00%, and 70.00%, respectively. GP73 expression was generally weak in HBV-C (Figure 1B), moderately positive in CHB (Figure 1C), strongly positive in severe hepatitis (Figure 1D), compensated LC (Figure 1E), and HCC (Figure 1F). Our IHC analysis indicated that GP73 expression and expression intensity in hepatocytes gradually increased with the progression of chronic hepatitis B.


Serum Golgi protein 73 (GP73) is a diagnostic and prognostic marker of chronic HBV liver disease.

Xu Z, Liu L, Pan X, Wei K, Wei M, Liu L, Yang H, Liu Q - Medicine (Baltimore) (2015)

GP73 protein expression in normal and chronic HBV-infected liver tissues. (A) IHC showed that a majority of hepatocytes in the normal liver tissue were negative for GP73 protein expression. (B) Weak GP73 staining was detected in the liver of a HBV-C patient without prominent necroinflammation. (C) Many hepatocytes were detected with moderate GP73 staining in the moderately inflamed liver. Strong GP73 positivity was detected in the liver with severe chronic hepatitis B (D), compensated liver cirrhosis (E), and HCC (F). (Magnification, ×200). HBV-C = HBV carriers, HCC = HBV-related primary hepatocellular carcinoma, IHC = immunohistochemical.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4554005&req=5

Figure 1: GP73 protein expression in normal and chronic HBV-infected liver tissues. (A) IHC showed that a majority of hepatocytes in the normal liver tissue were negative for GP73 protein expression. (B) Weak GP73 staining was detected in the liver of a HBV-C patient without prominent necroinflammation. (C) Many hepatocytes were detected with moderate GP73 staining in the moderately inflamed liver. Strong GP73 positivity was detected in the liver with severe chronic hepatitis B (D), compensated liver cirrhosis (E), and HCC (F). (Magnification, ×200). HBV-C = HBV carriers, HCC = HBV-related primary hepatocellular carcinoma, IHC = immunohistochemical.
Mentions: GP73 expression was detected in liver tissues of 16 patients with chronic hepatitis B. IHC staining results showed that a majority of hepatocytes in the normal liver tissue were negative for GP73 protein expression (Figure 1A). In patients with chronic HBV infections, GP73 was expressed with a scattered pattern in the cytoplasm of hepatocytes, but not in the infiltrating inflammatory cells. The detected GP73 positive cell percentages in HBV-C, CHB, severe hepatitis, compensated LC and HCC patients were about 15.00%, 45.00%, 75.00%, and 70.00%, respectively. GP73 expression was generally weak in HBV-C (Figure 1B), moderately positive in CHB (Figure 1C), strongly positive in severe hepatitis (Figure 1D), compensated LC (Figure 1E), and HCC (Figure 1F). Our IHC analysis indicated that GP73 expression and expression intensity in hepatocytes gradually increased with the progression of chronic hepatitis B.

Bottom Line: In patients with normal ALT levels, serum GP73 concentrations were significantly higher in patients with prominent hepatic inflammatory injury and fibrosis than in patients without hepatic inflammatory injury or fibrosis.Serum GP73 concentrations and GP73 protein expression were decreased in the liver tissues of patients whose ALT levels normalized after 1 year of ETV antiviral therapy.Changes in serum GP73 levels were closely associated with changes in liver injury severity, and, therefore, GP73 may be an effective new liver inflammatory injury biomarker, and could be useful for monitoring the prognosis of chronic HBV infectious patients with normal ALT levels.

View Article: PubMed Central - PubMed

Affiliation: From the Clinical Liver Center (ZX, Liguan Liu, XP, HY, QL); Central Laboratory of Clinical Hepatology (KW, MW); and Department of Pathology (Lifei Liu), The 180th Hospital of the People's Liberation Army, Quanzhou, China.

ABSTRACT
Alanine aminotransferase (ALT) is the most commonly used marker of liver injury, but normal ALT levels are seen in a proportion of chronic hepatitis B virus (HBV)-infected patients with severe liver injury. Golgi protein 73 (GP73) is a promising alternative marker of liver injury. This study assessed the relation between GP73 levels and liver disease severity, monitored the kinetic changes in GP73 levels in chronic HBV patients receiving entecavir (ETV) therapy, and investigated the potential diagnostic and prognostic values of serum GP73 as a new liver injury biomarker in chronic HBV infections. This study enrolled 1150 patients with chronic HBV infections, 200 of whom were retrospectively enrolled in this study after receiving 1 year of ETV treatment. GP73 expression in liver tissue was detected by immunohistochemistry. GP73 levels in single or serial serum samples were measured by enzyme-linked immunosorbent assay. Immunohistochemical analysis indicated that GP73 protein expression in the liver increased progressively with pathologic progression from nonexistent or mild hepatitis to severe hepatitis and cirrhosis during chronic HBV infection. Serum GP73 levels were positively correlated with the disease severity of chronic HBV infections (r = 0.58, P < 0.001). In patients with normal ALT levels, serum GP73 concentrations were significantly higher in patients with prominent hepatic inflammatory injury and fibrosis than in patients without hepatic inflammatory injury or fibrosis. Serum GP73 concentrations and GP73 protein expression were decreased in the liver tissues of patients whose ALT levels normalized after 1 year of ETV antiviral therapy. Changes in serum GP73 levels were closely associated with changes in liver injury severity, and, therefore, GP73 may be an effective new liver inflammatory injury biomarker, and could be useful for monitoring the prognosis of chronic HBV infectious patients with normal ALT levels.

Show MeSH
Related in: MedlinePlus